Distinguishing features of long COVID identified through immune profiling.
Nature · 2023 · 599 citations · Erica Breyman
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
The Lancet. Neurology · 2021 · 608 citations · Chafic Karam
Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
Cell · 2022 · 426 citations · Erica Breyman
Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life, and Participation.
American journal of physical medicine & rehabilitation · 2022 · 246 citations · Erica Breyman
Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 · 333 citations · Meenakshi Rana
Assessment of Cognitive Function in Patients After COVID-19 Infection.
JAMA network open · 2021 · 270 citations · Allison Navis
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Frontiers in neurology · 2023 · 78 citations · Chafic Karam
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.
Antimicrobial agents and chemotherapy · 2022 · 156 citations · Meenakshi Rana